article thumbnail

With new study results, Johnson & Johnson can tout Tremfya's efficacy across all skin tones

Fierce Pharma

The first biologic to win approval to treat moderate to severe psoriasis was Astellas’ now-discontinued Amevive (alefacept) in 2003, paving the way for significant progress in the disease space. | The VISIBLE trial is the first large-scale psoriasis study in only people of color, J&J said.

162
162
article thumbnail

470% price increases

World of DTC Marketing

Today, AbbVie charges approximately $77,000 for a year’s supply of Humira—470% more than when the drug was launched in 2003. Record Corporate Revenue Driven by Price Increases: Since 2003, AbbVie has collected over $107 billion in U.S. The graph below shows AbbVie’s and Amgen’s pricing for Humira and Enbrel from 2003 to 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AbbVie Exploits Offshore Subsidiaries to Avoid Paying Taxes

World of DTC Marketing

Since AbbVie began to sell Humira in 2003, the price of Humira has been raised 27 times. In 2021, AbbVie generated over $56 billion in worldwide sales, with over 77% of those sales made in the United States. Over the last four years, AbbVie has sold an astounding $62 billion Humira in the United States. .

Sales 269
article thumbnail

My 2003 New York Blackout Experience

Source Explorer

[link]. (..)

52
article thumbnail

Ten Ways to Think Differently About Small-to-Mid-Sized Pharma Launches

Eversana Intouch

Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. By 2018, that share had fallen by about half. Meanwhile, the number of companies launching their first drug during the decade preceding 2018 more than tripled.

Pharma 105
article thumbnail

FDA Approves Omalizumab to Reduce Food-Based Allergic Reactions in Adult and Pediatric Patients

Pharmacy Times

This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.

Food 57
article thumbnail

AbbVie appoints new Chief Scientific Officer

European Pharmaceutical Review

Dr Thakkar joined Abbott/AbbVie in 2003 and has progressed through several positions in clinical development, including group project director, immunology, as well as vice president and global regulatory affairs. In 2019, Dr Thakkar took on the role of vice president, global regulatory affairs and R&D quality assurance.

Medicine 105